LianBio (LIAN) FDA Approvals $0.05 +0.00 (+6.09%) As of 11/13/2026 Add Compare Share Share FDA Events Stock AnalysisChartCompetitorsFDA EventsSEC Filings LianBio's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by LianBio (LIAN). Over the past two years, LianBio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as CAMZYOS®. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. CAMZYOS® (mavacamten) FDA Regulatory Timeline and Events CAMZYOS® (mavacamten) is a drug developed by LianBio for the following indication: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Results - November 6,2026Results Phase 3Drug: CAMZYOS® (mavacamten)Announced Date: November 6, 2026Indication: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy Other Companies Involved: NYSE:BMY AnnouncementBristol Myers Squibb today presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, taking place November 6, 2026, in Chicago, Illinois.Read AnnouncementFDA approved - September 30,2026Fda Approved Drug: CAMZYOS® (mavacamten)Announced Date: September 30, 2026Indication: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy Other Companies Involved: NYSE:BMY AnnouncementBristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved CAMZYOS® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more.Read AnnouncementPresentation - August 25,2025Presentation Drug: CAMZYOS® (mavacamten)Announced Date: August 25, 2025Indication: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy Other Companies Involved: NYSE:BMY AnnouncementBristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology(ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain.AI SummaryBristol Myers Squibb announced that it will present new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid. The company will share results from the global COLLIGO-HCM observational study, which tracks real-world outcomes of Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) across five countries. Another highlight is a pooled monotherapy analysis of four Phase 3 trials, demonstrating the efficacy and safety of Camzyos alone in treating oHCM. These presentations build on long-term extension and real-world effectiveness data, showing symptom relief, improved exercise capacity and positive changes in heart structure. Additional oral sessions will feature results from the ODYSSEY-HCM Phase 3 trial in non-obstructive HCM and data on Eliquis (apixaban) through the BMS-Pfizer Alliance. Together, these findings reinforce Camzyos as the first and only approved cardiac myosin inhibitor for symptomatic oHCM, supporting its safety and benefits for diverse patient groups worldwide.Read Announcement LianBio FDA Events - Frequently Asked Questions Has LianBio received FDA approval? As of now, LianBio (LIAN) has not received any FDA approvals for its therapy in the last two years. What drugs has LianBio submitted to the FDA? In the past two years, LianBio (LIAN) has reported FDA regulatory activity for CAMZYOS® (mavacamten). What is the most recent FDA event for LianBio? The most recent FDA-related event for LianBio occurred on November 6, 2026, involving CAMZYOS® (mavacamten). The update was categorized as "Results," with the company reporting: "Bristol Myers Squibb today presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, taking place November 6, 2026, in Chicago, Illinois." What conditions do LianBio's current drugs treat? Currently, LianBio has one therapy (CAMZYOS® (mavacamten)) targeting the following condition: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Aclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA EventsCorbus Pharmaceuticals FDA EventsCardiff Oncology FDA EventsCytokinetics FDA EventsEstrella Immunopharma FDA EventsCybin FDA EventsIN8bio FDA EventsLantheus FDA EventsMediWound FDA EventsMetaVia FDA EventsRadiopharm Theranostics FDA EventsRein Therapeutics FDA EventsNuvation Bio FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Cocrystal Pharma FDA Events Tvardi Therapeutics FDA Events Quoin Pharmaceuticals FDA Events Quantum Biopharma FDA Events Dare Bioscience FDA Events Citius Pharmaceuticals FDA Events Lipocine FDA Events Optimi Health FDA Events Adial Pharmaceuticals FDA Events Cellectar Biosciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:LIAN last updated on 11/9/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredRIP USDIn 1974, a quiet deal between Henry Kissinger and the Saudis reshaped America's monetary order overnight, with...Porter & Company | SponsoredBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...Goldco Direct, LLC | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Results - November 6,2026Results Phase 3Drug: CAMZYOS® (mavacamten)Announced Date: November 6, 2026Indication: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy Other Companies Involved: NYSE:BMY AnnouncementBristol Myers Squibb today presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, taking place November 6, 2026, in Chicago, Illinois.Read Announcement
FDA approved - September 30,2026Fda Approved Drug: CAMZYOS® (mavacamten)Announced Date: September 30, 2026Indication: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy Other Companies Involved: NYSE:BMY AnnouncementBristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved CAMZYOS® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more.Read Announcement
Presentation - August 25,2025Presentation Drug: CAMZYOS® (mavacamten)Announced Date: August 25, 2025Indication: For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy Other Companies Involved: NYSE:BMY AnnouncementBristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology(ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain.AI SummaryBristol Myers Squibb announced that it will present new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid. The company will share results from the global COLLIGO-HCM observational study, which tracks real-world outcomes of Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) across five countries. Another highlight is a pooled monotherapy analysis of four Phase 3 trials, demonstrating the efficacy and safety of Camzyos alone in treating oHCM. These presentations build on long-term extension and real-world effectiveness data, showing symptom relief, improved exercise capacity and positive changes in heart structure. Additional oral sessions will feature results from the ODYSSEY-HCM Phase 3 trial in non-obstructive HCM and data on Eliquis (apixaban) through the BMS-Pfizer Alliance. Together, these findings reinforce Camzyos as the first and only approved cardiac myosin inhibitor for symptomatic oHCM, supporting its safety and benefits for diverse patient groups worldwide.Read Announcement